Literature DB >> 14736728

Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity.

Kostas Tsiakas1, Robert Steinfeld, Stephan Storch, Junji Ezaki, Zoltan Lukacs, Eiki Kominami, Alfried Kohlschütter, Kurt Ullrich, Thomas Braulke.   

Abstract

Late infantile neuronal ceroid lipofuscinosis (LINCL) is caused by the deficiency of the lysosomal tripeptidyl peptidase-I encoded by CLN2. We previously detected in two LINCL patients a homozygous missense mutation, p.Asn286Ser, that affects a potential N-glycosylation site. We introduced the p.Asn286Ser mutation into the wild-type CLN2 cDNA and performed transient expression analysis to determine the effect on the catalytic activity, intracellular targeting, and glycosylation of the CLN2 protein. Expression of mutant p.Asn286Ser CLN2 in HEK293 cells revealed that the mutant was enzymatically inactive. Western blot analysis demonstrated that at steady state the amounts of expressed p.Asn286Ser CLN2 were reduced compared with wild-type expressing cells. The rate of synthesis and the sorting of the newly synthesized p.Asn286Ser CLN2 in the Golgi was not affected compared with wild-type CLN2 protein. The electrophoretic mobility of the immunoprecipitated mutant p.Asn286Ser CLN2 was increased by approximately 2 kDa compared with the wild-type CLN2 protein, whereas deglycosylation led to the generation of polypeptides of the same apparent size. The data suggest that mutant p.Asn286Ser CLN2 lacks one oligosaccharide chain resulting in enzymatic inactivation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736728     DOI: 10.1093/glycob/cwh054

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  7 in total

Review 1.  Parkinson's disease pathogenesis from the viewpoint of small fish models.

Authors:  Hideaki Matsui; Ryosuke Takahashi
Journal:  J Neural Transm (Vienna)       Date:  2017-08-02       Impact factor: 3.575

Review 2.  Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.

Authors:  Sara E Mole; Ruth E Williams; Hans H Goebel
Journal:  Neurogenetics       Date:  2005-09-28       Impact factor: 2.660

3.  Simultaneous characterization of glyco- and phosphoproteomes of mouse brain membrane proteome with electrostatic repulsion hydrophilic interaction chromatography.

Authors:  Huoming Zhang; Tiannan Guo; Xin Li; Arnab Datta; Jung Eun Park; Jie Yang; Sai Kiang Lim; James P Tam; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-01-04       Impact factor: 5.911

4.  A critical tryptophan and Ca2+ in activation and catalysis of TPPI, the enzyme deficient in classic late-infantile neuronal ceroid lipofuscinosis.

Authors:  Salomon Kuizon; Kathleen DiMaiuta; Marius Walus; Edmund C Jenkins; Marisol Kuizon; Elizabeth Kida; Adam A Golabek; Daniel O Espinoza; Raju K Pullarkat; Mohammed A Junaid
Journal:  PLoS One       Date:  2010-08-03       Impact factor: 3.752

5.  Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.

Authors:  Jayita Guhaniyogi; Istvan Sohar; Kalyan Das; Ann M Stock; Peter Lobel
Journal:  J Biol Chem       Date:  2008-11-26       Impact factor: 5.157

Review 6.  Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function.

Authors:  Amanda L Getty; David A Pearce
Journal:  Cell Mol Life Sci       Date:  2010-08-01       Impact factor: 9.207

7.  Batten disease: biochemical and molecular characterization revealing novel PPT1 and TPP1 gene mutations in Indian patients.

Authors:  Jayesh Sheth; Mehul Mistri; Riddhi Bhavsar; Dhairya Pancholi; Mahesh Kamate; Neerja Gupta; Madhulika Kabra; Sanjiv Mehta; Sheela Nampoothiri; Arpita Thakker; Vivek Jain; Raju Shah; Frenny Sheth
Journal:  BMC Neurol       Date:  2018-12-12       Impact factor: 2.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.